Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia

Eva Kimby, Steven P. Treon, Athanasios Anagnostopoulos, Meletios Dimopoulos, Ramon Garcia-Sanz, Morie Gertz, Stephen Johnson, Veronique LeBlond, Jean Paul Fermand, David G. Maloney, Giampaolo Merlini, Pierre Morel, Enrica Morra, Gwen Nichols, Enrique M. Ocio, Roger Owen, Marvin Stone, Joan Bladé

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

This report by an international consensus panel updates current recommendations for defining clinical response in Waldenström's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.

Original languageEnglish (US)
Pages (from-to)380-383
Number of pages4
JournalClinical Lymphoma and Myeloma
Volume6
Issue number5
DOIs
StatePublished - Jan 1 2006

Fingerprint

Waldenstrom Macroglobulinemia
Nucleosides
Education
Biological Factors
Bone Marrow
Therapeutics
Proteins

Keywords

  • Bence Jones protein
  • Disease progression
  • Immunoglobulin M
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia. / Kimby, Eva; Treon, Steven P.; Anagnostopoulos, Athanasios; Dimopoulos, Meletios; Garcia-Sanz, Ramon; Gertz, Morie; Johnson, Stephen; LeBlond, Veronique; Fermand, Jean Paul; Maloney, David G.; Merlini, Giampaolo; Morel, Pierre; Morra, Enrica; Nichols, Gwen; Ocio, Enrique M.; Owen, Roger; Stone, Marvin; Bladé, Joan.

In: Clinical Lymphoma and Myeloma, Vol. 6, No. 5, 01.01.2006, p. 380-383.

Research output: Contribution to journalArticle

Kimby, E, Treon, SP, Anagnostopoulos, A, Dimopoulos, M, Garcia-Sanz, R, Gertz, M, Johnson, S, LeBlond, V, Fermand, JP, Maloney, DG, Merlini, G, Morel, P, Morra, E, Nichols, G, Ocio, EM, Owen, R, Stone, M & Bladé, J 2006, 'Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia', Clinical Lymphoma and Myeloma, vol. 6, no. 5, pp. 380-383. https://doi.org/10.3816/CLM.2006.n.013
Kimby, Eva ; Treon, Steven P. ; Anagnostopoulos, Athanasios ; Dimopoulos, Meletios ; Garcia-Sanz, Ramon ; Gertz, Morie ; Johnson, Stephen ; LeBlond, Veronique ; Fermand, Jean Paul ; Maloney, David G. ; Merlini, Giampaolo ; Morel, Pierre ; Morra, Enrica ; Nichols, Gwen ; Ocio, Enrique M. ; Owen, Roger ; Stone, Marvin ; Bladé, Joan. / Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia. In: Clinical Lymphoma and Myeloma. 2006 ; Vol. 6, No. 5. pp. 380-383.
@article{50d2ccc80bad4999b2deb24d208252a1,
title = "Update on recommendations for assessing response from the Third International Workshop on Waldenstr{\"o}m's macroglobulinemia",
abstract = "This report by an international consensus panel updates current recommendations for defining clinical response in Waldenstr{\"o}m's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.",
keywords = "Bence Jones protein, Disease progression, Immunoglobulin M, Relapse",
author = "Eva Kimby and Treon, {Steven P.} and Athanasios Anagnostopoulos and Meletios Dimopoulos and Ramon Garcia-Sanz and Morie Gertz and Stephen Johnson and Veronique LeBlond and Fermand, {Jean Paul} and Maloney, {David G.} and Giampaolo Merlini and Pierre Morel and Enrica Morra and Gwen Nichols and Ocio, {Enrique M.} and Roger Owen and Marvin Stone and Joan Blad{\'e}",
year = "2006",
month = "1",
day = "1",
doi = "10.3816/CLM.2006.n.013",
language = "English (US)",
volume = "6",
pages = "380--383",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "5",

}

TY - JOUR

T1 - Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia

AU - Kimby, Eva

AU - Treon, Steven P.

AU - Anagnostopoulos, Athanasios

AU - Dimopoulos, Meletios

AU - Garcia-Sanz, Ramon

AU - Gertz, Morie

AU - Johnson, Stephen

AU - LeBlond, Veronique

AU - Fermand, Jean Paul

AU - Maloney, David G.

AU - Merlini, Giampaolo

AU - Morel, Pierre

AU - Morra, Enrica

AU - Nichols, Gwen

AU - Ocio, Enrique M.

AU - Owen, Roger

AU - Stone, Marvin

AU - Bladé, Joan

PY - 2006/1/1

Y1 - 2006/1/1

N2 - This report by an international consensus panel updates current recommendations for defining clinical response in Waldenström's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.

AB - This report by an international consensus panel updates current recommendations for defining clinical response in Waldenström's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.

KW - Bence Jones protein

KW - Disease progression

KW - Immunoglobulin M

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=33646546982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646546982&partnerID=8YFLogxK

U2 - 10.3816/CLM.2006.n.013

DO - 10.3816/CLM.2006.n.013

M3 - Article

C2 - 16640813

AN - SCOPUS:33646546982

VL - 6

SP - 380

EP - 383

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 5

ER -